- Cabometyx has orphan drug status in the US
- Takeda has rights to all indications for Cabometyx in Japan
Exelixis, Inc. (NASDAQ:EXEL) announced on 9/19/18 that its... read more
Exelixis, Inc. (NASDAQ:EXEL) announced on 9/19/18 that its... read more
AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections... read more
Atomwise Inc., a leader in Artificial Intelligence (AI) for drug... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,